Abstract:Abstract Autologous T cells engineered to express a chimeric antigen receptor (CAR-T cells) have shown impressive outcomes in hematologic malignancies. However, safety concerns derived from the inability to control CAR-T cells in vivo remain a significant challenge to expand the application of CAR-T cell therapy. Switchable CAR-T cells can allow for turning on and off the activation and cytotoxicity of CAR-T cells in vivo, potentially increasing the safety of next-generation CART products. To this goal, CAR constructs targeting non-tumor antigens, e.g., haptens and peptide tags, can be designed and combined with tumor-targeting units that are fused to the hapten or peptide tag. In this study, we developed a novel switchable CAR-T system using cotinine as the hapten and an anti-cotinine CAR-T cell product. Of note, cotinine is physiologically absent in human and pharmacologically inert. A mouse antibody to cotinine was developed and successfully humanized. The anti-cotinine CAR confirmed to be displayed on T-cell surface. We first tested this approach to target epidermal growth factor receptor 2 (HER2) in ovarian cancer. To target HER2, we developed an affibody-based antigen binding domain characterized by high stability, broad spectrum of specificity, and feasibility of large scale chemical synthesis. In in vitro cytotoxicity and cytokine release assays, the activity of CAR-T cells was controlled by cotinine-tagged anti-HER2 affibody in a HER2-specific and dose-dependent manner. We synthesized the cotinine-tagged HER2 affibodies using single isoform cotinine and selected the optimal cotinine-tagged anti-HER2 affibody at the cotinine-based switchable CAR-T system. In an orthotopic ovarian cancer model using NSG mice engrafted with SKOV3, tumor regression was observed only when CAR-T cells were administered in combination with the cotinine-tagged HER2 affibody. In subsequent studies, we demonstrated that the cotinine-based switchable CAR-T system can be applied to other tumor targets such as mesothelin and epidermal growth factor receptor (EGFR). Additional studies are ongoing to determine the kinetics of the on and off CAR-T activation of this system and define the optimal dosing strategy to ensure anti-tumor effect or to interrupt toxicity. In conclusion, we have developed a novel switchable cotinine-based CAR-T system to control CAR-T function in vivo and that could be broadly applicable to wide variety of tumors. Disclosures Kim: AbClon Inc.: Current Employment. Lee: AbClon Inc.: Current Employment. Ruella: viTToria biotherapeutics: Research Funding; Tmunity: Patents & Royalties; AbClon: Consultancy, Research Funding; BMS, BAYER, GSK: Consultancy; Novartis: Patents & Royalties. Chung: AbClon Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding.

Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System

Switch-mediated Activation and Retargeting of CAR-T Cells for B-cell Malignancies

Engineering switchable and programmable universal CARs for CAR T therapy

Versatile strategy for controlling the specificity and activity of engineered T cells

Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments

Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (adv. Sci. 12/2023)

Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells

Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator

Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control.

Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand

Construction of a Versatile Fusion Protein for Targeted Therapy and Immunotherapy.

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells

A Novel Cotinine-Based System for Switchable Chimeric Antigen Receptor T Cell Immunotherapy

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo